Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Biomea Fusion (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
Thomas Butler, CEO and Board Chairman, will deliver a presentation on Wednesday, January 15, 2025, at 1:30 PM PT / 4:30 PM ET. The company's management team will also conduct one-on-one meetings throughout the conference, which runs from January 13 to January 16.
Interested parties can access a live audio webcast of the presentation through the company's investor relations website at investors.biomeafusion.com/news-events/events, with a replay available after the live presentation.
Biomea Fusion (Nasdaq: BMEA), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di piccole molecole covalenti orali per il diabete, l'obesità e i tumori geneticamente definiti, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare.
Thomas Butler, CEO e Presidente del Consiglio, terrà una presentazione mercoledì 15 gennaio 2025, alle 13:30 PT / 16:30 ET. Il team di gestione dell'azienda condurrà anche incontri individuali durante tutto il convegno, che si svolgerà dal 13 al 16 gennaio.
Le parti interessate possono accedere a una trasmissione audio in diretta della presentazione attraverso il sito web delle relazioni con gli investitori dell'azienda all'indirizzo investors.biomeafusion.com/news-events/events, con una registrazione disponibile dopo la presentazione dal vivo.
Biomea Fusion (Nasdaq: BMEA), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de pequeñas moléculas covalentes orales para la diabetes, la obesidad y los cánceres genéticamente definidos, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare.
Thomas Butler, CEO y Presidente de la Junta, realizará una presentación el miércoles 15 de enero de 2025, a la 1:30 PM PT / 4:30 PM ET. El equipo de gestión de la empresa también llevará a cabo reuniones uno a uno durante toda la conferencia, que se desarrolla del 13 al 16 de enero.
Las partes interesadas pueden acceder a una transmisión web en vivo de la presentación a través del sitio web de relaciones con inversores de la empresa en investors.biomeafusion.com/news-events/events, con una repetición disponible después de la presentación en vivo.
Biomea Fusion (Nasdaq: BMEA)는 당뇨병, 비만 및 유전적으로 정의된 암을 위한 경구용 공유결합 소분자를 개발하는 데 주력하는 임상단계의 생물 제약 회사로, 제43회 JP 모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다.
Thomas Butler CEO 겸 이사회 의장은 2025년 1월 15일 수요일, 오후 1시 30분 PT / 오후 4시 30분 ET에 발표를 진행할 예정입니다. 회사의 관리팀은 컨퍼런스 기간 동안 1:1 미팅도 진행할 예정이며, 컨퍼런스는 1월 13일부터 16일까지 개최됩니다.
관심 있는 분들은 회사의 투자자 관계 웹사이트인 investors.biomeafusion.com/news-events/events를 통해 발표의 실시간 오디오 웹캐스트에 접근할 수 있으며, 생중계 후에는 재방송도 제공됩니다.
Biomea Fusion (Nasdaq: BMEA), une entreprise biopharmaceutique en phase clinique axée sur le développement de petites molécules covalentes orales pour le diabète, l'obésité et les cancers génétiquement définis, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare.
Thomas Butler, PDG et Président du Conseil, présentera une intervention le mercredi 15 janvier 2025, à 13h30 PT / 16h30 ET. L'équipe de direction de l'entreprise mènera également des réunions individuelles tout au long de la conférence, qui se déroulera du 13 au 16 janvier.
Les parties intéressées peuvent accéder à un webcast audio en direct de la présentation via le site Internet des relations investisseurs de l'entreprise à l'adresse investors.biomeafusion.com/news-events/events, avec un replay disponible après la présentation en direct.
Biomea Fusion (Nasdaq: BMEA), ein biopharmazeutisches Unternehmen in klinischen Phasen, das sich auf die Entwicklung von oralen kovalenten kleinen Molekülen für Diabetes, Adipositas und genetisch definierte Krebserkrankungen konzentriert, hat seine Teilnahme an der 43. Jahreskonferenz von J.P. Morgan Healthcare angekündigt.
Thomas Butler, CEO und Vorsitzender des Vorstands, wird am Mittwoch, den 15. Januar 2025, um 13:30 Uhr PT / 16:30 Uhr ET eine Präsentation halten. Das Management-Team des Unternehmens wird auch Einzelgespräche während der gesamten Konferenz führen, die vom 13. bis 16. Januar dauert.
Interessierte Parteien können über die Investor-Relations-Website des Unternehmens unter investors.biomeafusion.com/news-events/events auf einen Live-Audio-Webcast der Präsentation zugreifen, mit einer Wiederholung, die nach der Live-Präsentation verfügbar ist.
- None.
- None.
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced today that Thomas Butler, Chief Executive Officer and Chairman of the Board, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Additionally, Biomea’s management team will be hosting one-on-one meetings throughout the conference, taking place from January 13 to January 16.
A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media section of Biomea’s website at https://investors.biomeafusion.com/news-events/events. A replay of the webcast will be available following the live presentation.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to significantly improve disease treatments for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Ramses Erdtmann
COO & President of Biomea Fusion
re@biomeafusion.com
FAQ
When is Biomea Fusion (BMEA) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Biomea Fusion's (BMEA) J.P. Morgan Healthcare Conference presentation?
What therapeutic areas does Biomea Fusion (BMEA) focus on?
What dates will Biomea Fusion (BMEA) be available for one-on-one meetings at the J.P. Morgan conference?
